Beximco Pharmaceuticals PLC (AIM: BXP), the Bangladesh-based generic medicines manufacturer and active pharmaceutical ingredient producer, has published its unaudited financial results for the first quarter ended 30 September 2026. The company reported net revenue of Tk 14.66 billion and profit after tax of Tk 2.60 billion, both ahead of the equivalent period a year earlier. The results, released simultaneously to the Dhaka and Chittagong Stock Exchanges, demonstrate continued top-line and earnings momentum at the AIM-listed pharma group despite what the company describes as ongoing macroeconomic challenges.

Key Points

  • Beximco Pharmaceuticals PLC (AIM: BXP), LEI: 213800IMBBD6TIOQGB56
  • Q1 FY2026-27 net revenue rose to Tk 14,657,933 thousand from Tk 13,794,829 thousand in Q1 FY2025-26, with profit after tax increasing from Tk 2,401,261 thousand to Tk 2,596,945 thousand year-on-year
  • Earnings per share improved to Tk 5.72 from Tk 5.30; net asset value per share stood at Tk 144.90 as at 30 September 2026
  • Investors may be watching the company's ability to sustain revenue and profit growth amid Bangladesh macroeconomic pressures and global regulatory developments affecting its more-than-50-country export footprint

Beximco Pharma Q1 Revenue and Profit Growth Year-on-Year

For the three months ended 30 September 2026, Beximco Pharma generated net revenue of Tk 14,657,933 thousand, compared with Tk 13,794,829 thousand in the same quarter of the prior year. Gross profit rose to Tk 7,174,983 thousand from Tk 6,662,080 thousand. Profit from operations reached Tk 3,398,464 thousand, up from Tk 3,293,746 thousand a year earlier. After accounting for finance costs and tax, profit after tax attributable to owners of the company came to Tk 2,553,261 thousand, with the remainder attributable to non-controlling interests, bringing total group profit after tax to Tk 2,596,945 thousand.

Strengthened Balance Sheet and Cash Position at 30 September 2026

Total assets increased to Tk 83,520,640 thousand as at 30 September 2026, up from Tk 81,139,566 thousand at 30 June 2026. Total equity expanded to Tk 68,790,192 thousand from Tk 66,194,354 thousand over the same period, reflecting retained profit generation during the quarter. Cash and cash equivalents grew notably to Tk 8,466,259 thousand from Tk 6,668,012 thousand at the prior year-end. Net operating cash flow per share rose to Tk 8.06 from Tk 6.14 in the equivalent prior-year period, while total liabilities fell marginally to Tk 14,730,448 thousand from Tk 14,945,212 thousand.

Broad Product Portfolio and Global Regulatory Certifications Underpin Beximco's Export Model

Founded in 1976 and headquartered in Bangladesh, Beximco Pharma manufactures a wide range of dosage forms including tablets, capsules, intravenous fluids, metered dose inhalers, insulins, prefilled syringes, and oral soluble films, among others. Its manufacturing facilities carry regulatory certifications from authorities in the USA, Europe, Australia, Canada, the GCC, and Latin America, supporting a commercial presence across more than 50 countries. The company also undertakes contract manufacturing for multinational and global generic pharmaceutical companies, providing an additional revenue stream beyond its domestic Bangladesh business.

Managing Director Cites Resilience Despite Macroeconomic Headwinds

Managing Director S. M. Rabbur Reza stated in the announcement that the results "demonstrate the underlying strength and resilience of Beximco Pharma's business," adding that the company had "continued to deliver revenue and profitability growth into the new financial year" despite ongoing macroeconomic challenges. The company employs more than 6,000 people and describes its ambition as becoming one of the most admired companies in the region. A key company-specific risk remains Bangladesh's broader economic environment, which management acknowledged could continue to present headwinds as the financial year progresses.